Us Too! 
These articles have been reprinted from the July/August 1999 issue of Us Too! International, INC.


The June 16 Journal of the National Cancer Institute (NCI) includes three papers suggesting that PSA testing has positively impacted prostate cancer inci­dence and mortality. Incidence data derived from the NCI's Surveillance, Epidemiology and End Results (SEER) Program and mortality data from the Center for Health Statistics show the '1dramat-ic decrease in distant stage disease prostate cancer and the decrease in mortality that has occurred," according to Dr. Benjamin Hankey of NCI. Evidence suggests that screening is contributing to the mortality decrease. Among white men, incidence of prostate cancer increased sharply in 1989 before peaking in 1992 and then declin­ing. The decline in the incidence of and mortality from distant stage disease was first noted in 1991, and followed by a decrease in localized and regional stage dis­ease in 1992. These trends are "consistent with a screening effect," according to Hankey. These and other factors "hold out promise that PSA testing may lead to a sustained decline in prostate cancer mortality," he notes, adding, "We'll know in the next five to ten years."

CaverMap Demonstrates Nerve-Sparing Results

As reported in an earlier Hot Sheet, the surgical device CaverMap utilizes an intraopera­tive nerve stimulator and a sensi­tive detector to determine the location and pathways of nerves during radical prostatectomy surgery. A probe tip stimulates suspect tissue and the product detects nerve involvement by monitoring minute penile changes. Surgeons use such information to determine optimum dissection patterns in each patient. CaverMap was tested by six clini­cal institutions across Canada in a Randomized, Single Blinded, Multi-Center Clinical trial, present­ed recently at the Annual American Urological Association meeting in Dallas, TX. Doctors used the CaverMap tool to guide dissections and confirm nerve function during and at the end of procedures. 

When attempted, bilateral nerve sparing was achieved in 73 percent of study patients, com­pared to only 56 percent of con­trol patients. Also, CaverMap intraoperative "confirmation" of nerve function proved a good indicator of return of erectile function by a 12 months follow-up sexual function questionnaire. 

Calling it a "promising new technology," Laurence Klotz M.D., Professor of Urology at University of Toronto says, "Until now, surgeons have relied solely upon anatomical landmarks and experience to locate and avoid damaging the cavernosal nerves responsible for erectile function. Use of CaverMap... has potential...for improved nerve-sparing radical prostatectomy results." Patients facing surgery should ask their surgeons about this new technol­ogy.

Genetic Process Could be Reversible

A common genetic process that could be reversible is linked to nearly 90 percent of prostate cancers, according to Johns Hopkins researchers in a study appearing in Nature Medicine. Most prostate cancers may involve a process called gene switching, which occurs when certain members of a gene fami­ly switch "on" while others in the family switch "off." Says molecu­lar pathologist Gary Pasternack, M.D., Ph.D., who led the research team, "Someday it's likely we can reverse switching with drugs." Prostate cancer has the potential of being cor­rected without using typical gene therapy, he says. 

Scientists used molecular probes to highlight and compare gene activity in cancer patients' normal prostate tissue with that of their tumors and found clear evidence the gene pp32 was switched on in normal cells but generally switched off in cancer cells. Earlier studies by the team showed pp32 acts as a suppres­sor to keep cells from turning malignant. Close relatives of the gene, pp32rl and pp32r2, encourage tumor growth and are present and were turned on in perhaps 90 percent of the cases studied. Switching could be a fundamental process in cancer, researchers say; it has already been linked with common forms of breast cancer.“If we can understand how the switching works, what controls it, we can potentially reverse it,” Pasternack says, “That’s our next task.”The team hopes to screen and find drugs for the purpose within two years.

Model Explains Increased Incidence, Higher Mortality rate in Black Men

It has been noted for many years that African American men suffer both a higher incidence and mortality rate from prostate can­cer. While genetic and environ­mental factors contribute to dis­ease causation in both races, a unifying theme is needed to explain many unique observa­tions regarding prostate cancer in blacks. A recent article in Urology offers a conceptualiza­tion. 

Although incidence rates rose dramatically in both races in the early 1990's, the higher rate in blacks has been documented for more than 20 years with differ­ences most disparate in men under 65 years old. The mortality rate is also greater in blacks, again with greater disparity noted in younger men. Mortality rates are similar for blacks and whites diagnosed after age 70. 

One classic characteristic of prostate cancer in black men is later stage. Delay in detection caused by cultural issues (i.e.: access to healthcare, knowledge of the disease, economic factors, fear of therapy and distrust of a predominantly white medical establishment) may lead to a higher stage at time of initial ther­apy and a worse outcome for blacks. Data also suggests black men eat more animal fat, which is linked to greater prostate can­cer risk. Recent autopsy studies show small, latent cancers occur at similar frequency in both races between 20-80 years. Yet more high grade prostatic intraepithelial neoplasia (PIN) has been identi­fied in blacks. Increasing data also confirms that blacks have a higher androgenic stimulation as well as generally higher Gleason scores. 

Two researchers hypothesize that PIN is a precursor of Gleason grade 4 cancers: "The data sup­port a biologic etiology of increased incidence with epigenet­ic factors affecting stage at diag­nosis that could be circumvented by earlier detection. Cultural issues alone in black men would tend to lower, not raise, detec­tion and incidence; thus, a biolog­ic influence must be entertained. However, epigenetic factors such as diet, detection practices or androgenic stimulation may explain many other factors relat­ed to stage and presentation and mortality." 

Normal prostatic epithelium can undergo malignant transfor­mation by at least two pathways, leading to either well-differentiat­ed (Gleason grades 2 and 3) latent carcinomas predominantly in older men or high-grade PIN which, through additional muta­tions, could lead to morphologi­cally high-grade cancer, Gleason grade 4 and a higher frequency of Gleason score 7 or higher cancers. Because of greater genetic insta­bility of PIN, mutations occur at a younger age. The growth of the cancer is under the epigenetic influence of diet, androgenic stim­ulation, with cultural or detection issues contributing to a delay in diagnosis. "In the case of prostate cancer in black men, an increase of PIN establishes the setting for the sequence of events that explain the epidemiological and pathologic findings," the authors write. "There is opportunity for early detection to allow therapy before a prolonged influence of epigenetic factors. Through earli­er intervention, advanced prostate cancer occurs less fre­quently and the disparity in pathologic extent of disease between blacks and whites dimin­ishes." The model suggests piv­otal issues for prostate cancer in blacks are higher incidence of PIN and high-grade cancers.  (Source: 'A Unifying Model to Explain the Increased Incidence and Higher Mortality of Prostate Cancer in Black Men" by James Mon tie and Kenneth Pienta.)

 

Back to Top
 

 

GOLD UROLOGY Journal
Surgical Techniques
Initiatives
Cancer Research
Discovery Health
Urology Channel
OncoLink
Mediconsult
Prostate Cancer Educational Council
Us Too!
cancerfacts.com
Virgil's Online Guide to Fighting Prostate Cancer